Skip to main content
Premium Trial:

Request an Annual Quote

CORRECTED: Compugen Posts Q1 Revenue Increase

This story has been corrected from a previous version that misstated the company's cash holdings.


SAN FRANCISCO, April 24 - Compugen on Wednesday posted increased revenues and a decreased loss for the first quarter 2002.


For the three months ended March 31, the company reported revenues of $2.8 million, compared with $2.2 million in the same period one year ago.


Compugen also said that net losses decreased to $3.2 million, or $.12 a share in the first quarter of 2002, compared with $3.6 million, or $.14 a share one year ago. R&D spending decreased roughly $100,000 year-over-year to approximately $3.4 million.


Compugen said it has $73.6 million in cash, cash equivalents, and short and long term cash deposits and corporate bonds, down from $78.5 million as of December 31, 2001.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.